Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Marinus Pharmaceuticals Inc’s stock clocked out at $1.51, up 4.14% from its previous closing price of $1.45. In other words, the price has increased by $4.14 from its previous closing price. On the day, 1.61 million shares were traded. MRNS stock price reached its highest trading level at $1.65 during the session, while it also had its lowest trading level at $1.48.
Ratios:
To gain a deeper understanding of MRNS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.01 and its Current Ratio is at 4.07. In the meantime, Its Debt-to-Equity ratio is 6.58 whereas as Long-Term Debt/Eq ratio is at 5.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on April 16, 2024, Downgraded its rating to Neutral and sets its target price to $2 from $20 previously.
On April 15, 2024, RBC Capital Mkts Downgraded its rating to Sector Perform which previously was Outperform and also lowered its target price recommendation from $24 to $3.
Oppenheimer Downgraded its Outperform to Perform on August 11, 2023, whereas the target price for the stock was revised from $14 to $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 20 ’24 when Shafer Christina sold 2,153 shares for $9.56 per share. The transaction valued at 20,583 led to the insider holds 60,308 shares of the business.
MANNING MARTHA E sold 1,894 shares of MRNS for $18,126 on Feb 20 ’24. The SVP, GEN. COUNSEL & CORP. SEC. now owns 52,966 shares after completing the transaction at $9.57 per share. On Feb 16 ’24, another insider, Braunstein Scott, who serves as the CHAIRMAN AND CEO of the company, sold 11,850 shares for $9.94 each. As a result, the insider received 117,789 and left with 223,512 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNS now has a Market Capitalization of 82945808 and an Enterprise Value of 42580296. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.66 while its Price-to-Book (P/B) ratio in mrq is 4.92. Its current Enterprise Value per Revenue stands at 1.374 whereas that against EBITDA is -0.338.
Stock Price History:
The Beta on a monthly basis for MRNS is 1.12, which has changed by -0.84170306 over the last 52 weeks, in comparison to a change of 0.22379243 over the same period for the S&P500. Over the past 52 weeks, MRNS has reached a high of $11.26, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -78.00%, while the 200-Day Moving Average is calculated to be -80.89%.
Shares Statistics:
It appears that MRNS traded 1.84M shares on average per day over the past three months and 1844220 shares per day over the past ten days. A total of 54.58M shares are outstanding, with a floating share count of 51.15M. Insiders hold about 6.40% of the company’s shares, while institutions hold 101.78% stake in the company. Shares short for MRNS as of 1713139200 were 4515119 with a Short Ratio of 2.45, compared to 1710460800 on 3573079. Therefore, it implies a Short% of Shares Outstanding of 4515119 and a Short% of Float of 8.25.
Earnings Estimates
At present, 11.0 analysts are actively evaluating the performance of Marinus Pharmaceuticals Inc (MRNS) in the stock market.On average, analysts expect EPS of -$0.66 for the current quarter, with a high estimate of -$0.61 and a low estimate of -$0.79, while EPS last year was -$0.67. The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.48 and low estimates of -$0.68.
Analysts are recommending an EPS of between -$1.7 and -$2.98 for the fiscal current year, implying an average EPS of -$2.19. EPS for the following year is -$1.29, with 11.0 analysts recommending between -$0.65 and -$2.31.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $9.12M. It ranges from a high estimate of $15.26M to a low estimate of $7.3M. As of the current estimate, Marinus Pharmaceuticals Inc’s year-ago sales were $10.38MFor the next quarter, 11 analysts are estimating revenue of $9.59M. There is a high estimate of $12.1M for the next quarter, whereas the lowest estimate is $7.91M.
A total of 11 analysts have provided revenue estimates for MRNS’s current fiscal year. The highest revenue estimate was $55.3M, while the lowest revenue estimate was $33.22M, resulting in an average revenue estimate of $40.84M. In the same quarter a year ago, actual revenue was $30.99MBased on 11 analysts’ estimates, the company’s revenue will be $61.88M in the next fiscal year. The high estimate is $127.7M and the low estimate is $41.5M.
